Overview of the Meeting by Session Chairs

4:00 CAR-Independent Gene Transfer to Accomplish Efficient, and Specific Genetic Modification of Target Cells Via Adenoviral Vectors
David T. Curiel, M.D.
University of Alabama at Birmingh

4:30 Lentiviral Vectors
Inder Verma, Ph.D.
The Salk Institute

5:00 Challenges of Genetic Disease: Gene Addition or Gene Repair
R. Michael Blaese, M.D.
Kimeragen, Inc.

5:30 Non-Viral Gene Transfer
Jon Wolff, M.D.
University of Wisconsin

6:00 Cocktails

Keynote Address

8:30 Self-Assembly and Soft Lithography: An Overview
George Whitesides, Ph.D.
Harvard University

Targeting, Delivery & Immunogenicity
Chair: David Curiel, M.D.

9:00 DNA Nanotechnology
Nadrian Seeman, Ph.D.
New York University

9:30 Self Assembled Structures of Lipid-DNA Nonviral Gene Delivery Systems
Cyrus Safinya, Ph.D.
University of California, Santa Barbara

10:00 Constitutive and Regulated Expression in the Systemic Delivery of Erythropoietin Following Skeletal Muscle Transduction with DNA Viral Vectors
James M. Wilson, M.D., Ph.D.
University of Pennsylvania

10:30 Coffee

11:00 Uptake of Cationic Liposomes by Normal and Angiogenic Endothelial Cells In Vivo
Donald M. McDonald, M.D., Ph.D.
University of California, San Francisco

11:30 Polymer Based Systems for Tumor-Targeted Gene Delivery
Ernst Wagner, Ph.D.
Boehringer-Ingelheim Austria

12:00 Luncheon

1:30 Generation of a Mouse Model for Studying AAV Targeted Integration
Richard Jude Samulski, Ph.D.
University of North Carolina

2:00 The Role of Microtubule-Dependent Motility During Intracellular Trafficking of Vector Genome to the Nucleus
Philip L. Leopold, Ph.D.
Weill Medical College of Cornell University

2:30 LPD Nanoparticles for Gene Delivery
Leaf Huang, Ph.D.
University of Pittsburgh

3:00 In Vivo Gene Transfer with Retrovirus Vectors
Theodore Friedmann, M.D.
University of California School of Medicine, San Diego

3:30 Coffee

Expression Control
Chair: Inder Verma, Ph.D.

4:00 Regulating the Regulators
Helen M. Blau, Ph.D.
Stanford University School of Medicine

4:30 Large Chimeric Circular MACs for Gene Therapy and Animal Transgenesis
Jean-Michel H. Vos, D.Sc.
University of North Carolina

5:00 Wine & Cheese

Preclinical & Clinical
Chair: R. Michael Blaese, M.D.

8:30 Evaluation of AAV Vectors For the Treatment of Hemophilia A and B
Alan McClelland, Ph.D.
Avigen, Inc.

9:00 TBA
Barrie Carter, Ph.D.
Targeted Genetics Corp.

10:00 Systemic Delivery of Tumor-targeted p53 Gene Therapy Results in Chemo/Radiosensitization
Esther Chang, Ph.D.
Georgetown University Medical Center

10:30 Coffee

11:00 Fas Ligand (CD95L) and Cancer Gene Therapy
Gary J. Nabel, M.D., Ph.D.
National Institutes of Health

11:30 Pharmaceutical Gene Medicines for Local and Systemic Therapy
Alain Rolland, Pharm. D., Ph.D.
Valentis, Inc.

12:00 Luncheon

12:45 The Novartis Approach to Gene Therapy
J. Tyler Martin, M.D.
Novartis

Emerging Technologies
Chair: Jon A. Wolff, M.D.

1:30 Sequence-Specific Gene Targeting Using Triplex Strategies
Claude Helene, Ph.D.
Museum National d'Histoire Naturelle

2:00 Nonviral Vectors for the Treatment of Disease
Nancy Smyth Templeton, Ph.D.
Baylor College of Medicine

2:30 PNA Dependent Gene Chemistry to Control Plasmid Delivery and Expression
Philip Felgner, Ph.D.
Gene Therapy Systems, Inc.

3:00 Targeting Adenovirus Vectors
Thomas J. Wickham, Ph.D.
GenVec, Inc.

3:30 Coffee

Roundtable: Building the Infrastructure

4:00 J. Tyler Martin, M.D.
Novartis
Kenneth A. Sorensen, Ph.D.
Muzinich & Co.
Kenneth Chahine, J.D., Ph.D.
Avigen Inc.